日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial

ER+HER2 转移性乳腺癌中赖氨酸乙酰转移酶 KAT6 的抑制:一项 1 期试验

Toru Mukohara, Yeon Hee Park, David Sommerhalder, Kan Yonemori, Erika Hamilton, Sung-Bae Kim, Jee Hyun Kim, Hiroji Iwata, Toshinari Yamashita, Rachel M Layman, Monica Mita, Timothy Clay, Yee Soo Chae, Catherine Oakman, Fengting Yan, Gun Min Kim, Seock-Ah Im, Geoffrey J Lindeman, Hope S Rugo, Marlon

Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients

期研究利用一种具有 Toll 样受体刺激作用的新型抗原呈递细胞靶向疫苗来诱导癌症患者对自身抗原的免疫力

Michael A Morse, Robert Chapman, John Powderly, Kimberly Blackwell, Tibor Keler, Jennifer Green, Renee Riggs, Li-Zhen He, Venky Ramakrishna, Laura Vitale, Biwei Zhao, Stephen A Butler, Amy Hobeika, Takuya Osada, Thomas Davis, Timothy Clay, H Kim Lyerly

CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting

基于 CD34 的基因工程人类 T 细胞富集用于临床可显著增强肿瘤靶向性

Håkan Norell, Yi Zhang, James McCracken, Telma Martins da Palma, Aaron Lesher, Yueying Liu, Jeffrey J Roszkowski, Anquanette Temple, Glenda G Callender, Timothy Clay, Rimas Orentas, José Guevara-Patiño, Michael I Nishimura

The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients

抗VEGF治疗对癌症患者未成熟髓系细胞和树突状细胞的影响

Takuya Osada, Gabriel Chong, Robert Tansik, Timothy Hong, Neil Spector, Rakesh Kumar, Herbert I Hurwitz, Inderjit Dev, Andrew B Nixon, H Kim Lyerly, Timothy Clay, Michael A Morse